Imbria Pharmaceuticals

Imbria Pharmaceuticals company information, Employees & Contact Information

Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits. The lead product candidate, ninerafaxstat, is currently in Phase 2 clinical development in three indications: nHCM, stable angina, and HFpEF. For additional information, please visit www.imbria.com.

Company Details

Employees
13
Founded
-
Address
265 Franklin Street,
Email
in****@****ria.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
imbria.com
HQ
Boston, Massachusetts
Looking for a particular Imbria Pharmaceuticals employee's phone or email?

Imbria Pharmaceuticals Questions

News

Imbria Pharmaceuticals, HCMS Team Up to Support Fortitude-HCM Trial - Diagnostic and Interventional Cardiology

Imbria Pharmaceuticals, HCMS Team Up to Support Fortitude-HCM Trial Diagnostic and Interventional Cardiology

Imbria Pharmaceuticals Partners with Hypertrophic Cardiomyopathy Association to Support FORTITUDE-HCM Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy - Yahoo Finance

Imbria Pharmaceuticals Partners with Hypertrophic Cardiomyopathy Association to Support FORTITUDE-HCM Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy Yahoo Finance

Imbria Pharmaceuticals Strengthens Leadership with New Board and Key Clinical Appointments - GlobeNewswire

Imbria Pharmaceuticals Strengthens Leadership with New Board and Key Clinical Appointments GlobeNewswire

Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - GlobeNewswire

Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO GlobeNewswire

Imbria Pharmaceuticals Appoints Physician-Scientist Albert M. Kim, MD, PhD, as Chief Medical Officer - GlobeNewswire

Imbria Pharmaceuticals Appoints Physician-Scientist Albert M. Kim, MD, PhD, as Chief Medical Officer GlobeNewswire

Imbria Pharmaceuticals to Participate at SVB Leerink Biopharma Private Company Connect - Business Wire

Imbria Pharmaceuticals to Participate at SVB Leerink Biopharma Private Company Connect Business Wire

Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25 - GlobeNewswire

Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25 GlobeNewswire

Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25) - GlobeNewswire

Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25) GlobeNewswire

Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy - Yahoo Finance

Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy Yahoo Finance

Imbria Pharmaceuticals Announces Initiation of Enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the Safety, Tolerability, and Efficacy of IMB-1018972 (IMB-101) in Patients With Non-Obstructive Hypertrophic Cardiomyopathy - Business Wire

Imbria Pharmaceuticals Announces Initiation of Enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the Safety, Tolerability, and Efficacy of IMB-1018972 (IMB-101) in Patients With Non-Obstructive Hypertrophic Cardiomyopathy Business Wire

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24 - Yahoo Finance

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24 Yahoo Finance

Top Imbria Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant